177 related articles for article (PubMed ID: 29262741)
1. Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU.
Samson AAS; Park S; Kim SY; Min DH; Jeon NL; Song JM
J Liposome Res; 2019 Mar; 29(1):44-52. PubMed ID: 29262741
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of clusterin alters mitochondrial dynamics, facilitates necrosis in camptothecin-induced cancer stem cells.
Arumugam P; Samson A; Ki J; Song JM
Cell Biol Toxicol; 2017 Jun; 33(3):307-321. PubMed ID: 28064403
[TBL] [Abstract][Full Text] [Related]
3. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
[TBL] [Abstract][Full Text] [Related]
5. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.
Xue HY; Wong HL
Eur J Pharm Biopharm; 2012 May; 81(1):24-32. PubMed ID: 22369881
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
7. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
9. DOTAP functionalizing single-walled carbon nanotubes as non-viral vectors for efficient intracellular siRNA delivery.
Li H; Hao Y; Wang N; Wang L; Jia S; Wang Y; Yang L; Zhang Y; Zhang Z
Drug Deliv; 2016; 23(3):840-8. PubMed ID: 24892622
[TBL] [Abstract][Full Text] [Related]
10. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
[TBL] [Abstract][Full Text] [Related]
11. The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines.
Parra E; Ferreira J
Oncol Rep; 2010 Apr; 23(4):1159-65. PubMed ID: 20204305
[TBL] [Abstract][Full Text] [Related]
12. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcyclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Fu H; Zhang Z; He Q
J Pharm Sci; 2015 Feb; 104(2):476-84. PubMed ID: 25256603
[TBL] [Abstract][Full Text] [Related]
13. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
14. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
[TBL] [Abstract][Full Text] [Related]
17. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
Şalva E; Turan SÖ; Eren F; Akbuğa J
Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
[TBL] [Abstract][Full Text] [Related]
18. Optimal combination of cationic lipid and phospholipid in cationic liposomes for gene knockdown in breast cancer cells and mouse lung using siRNA lipoplexes.
Hattori Y; Tang M; Torii S; Tomita K; Sagawa A; Inoue N; Yamagishi R; Ozaki KI
Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35686555
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
20. AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells.
Rafael D; Gener P; Andrade F; Seras-Franzoso J; Montero S; Fernández Y; Hidalgo M; Arango D; Sayós J; Florindo HF; Abasolo I; Schwartz S; Videira M
Drug Deliv; 2018 Nov; 25(1):961-972. PubMed ID: 29667444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
